Camurus Deal History & Licensing Activity
Camurus is a biotech headquartered in Italy. Over the past three years, Camurus has been involved in 3 licensing and acquisition transactions, with a primary focus on Peptides (6 deals). The company currently has 2 active clinical trials, primarily in Metabolic.
Deals (12mo)
2
Active Trials
2
Top Modality
Peptides
Focus Area
Metabolic
Camurus Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Camurus in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| GLP-1, GIP, and other incretin molecules | Lilly | Peptides | Unknown | collaboration | Jul 2025 |
| long-acting GLP-1 and incretin delivery technology | Eli Lilly | Peptides | Preclinical | collaboration | Jul 2025 |
| long-acting GLP-1/incretin technology | Lilly | Peptides | Unknown | license | Jun 2025 |
Camurus Pipeline Focus
Therapeutic areas and modalities where Camurus is most active based on deal history and clinical trial data.
Camurus Strategic Signals
Key indicators of Camurus's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Camurus Clinical Pipeline
Camurus has 2 active clinical trials across 2 development phases.
1
Phase 2
1
Phase 3
See How Your Asset Matches Camurus's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Camurus Licensing & Deal Activity
Camurus is a biotech company based in Italy that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Camurus ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Camurus include Metabolic (6 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, Camurus has shown particular interest in peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Camurus and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Camurus's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.